Northwell Health’s Feinstein Institutes for Medical Research received a $500,000 RADx Tech award to develop a non-invasive endometriosis biomarker test using menstrual samples. The project—part of the Research OutSmarts Endometriosis (ROSE) effort—aims to replace invasive surgical diagnosis with an FDA-aimed, assay-driven screening approach. The work is based on single-cell RNA sequencing of menstrual samples to generate a biomarker panel, with the ROSE program now enrolling more than 3,700 participants. Feinstein previously received $1 million from the Northwell Innovation Challenge in 2018 and $350,000 via a RADx Tech ACT ENDO challenge. For biotech stakeholders, the award highlights federal prioritization of diagnostics in women’s health and the growing use of transcriptomic signals in accessible specimen types. The sector will monitor assay validation, prospective study outcomes, and subsequent FDA pathway milestones.